IPX233-B14-02: Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteers

Trial Profile

IPX233-B14-02: Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteers

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs IPX 233 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 22 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to Australian New Zealand Clinical Trials Registry
    • 24 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top